LaNova Medicines Launches R&D Center after Relocation

SHANGHAI, November 29, 2021 - LaNova Medicines has completed the relocation of its Shanghai R&D Center and the operations has officially started. The R&D center is located at the Zhangjiang District of Shanghai, which is also known as the “China Pharmaceutical Valley”, covering an area of nearly 1,000 square meters. At the launch ceremony, Dr. Crystal Qin, Chairman and CEO of the company, said: “With the top-notch research facilities at the center, LaNova Medicines will continue to develop new drugs to benefit global cancer patients.”

Since its establishment two years ago, LaNova Medicine has independently established multiple R&D platforms for transmembrane protein expression including monoclonal antibodies, antibody conjugates, and bi-specific antibody drugs from scratch. The company has submitted over a dozen of global patents and advanced 3 products in multiple clinical trials in China, United States, and Australia.